This site is intended for healthcare professionals only
LoginRegister
GSK gets positive EMA Committee opinion recommending Momelotinib for myelofibrosis patients with anaemiaGSK gets positive EMA Committee opinion recommending Momelotinib for myelofibrosis patients with...
Bayer Aflibercept 8 mg recommended for approval in EUBayer Aflibercept 8 mg recommended for approval in EU
Boehringer Ingelheim, AnGes sign manufacturing agreement for HGF gene therapy productRznomics enters clinical trial collaboration with Roche to evaluate RZ-001 in combo with anti-PDL1...
Sandoz opens two new European facilitiesSandoz opens two new European facilities
CDSCO Expert Panel Backs Akums Faropenem Dispersible Tablets, Grants CT, BE WaiversAkums Pharma gets CDSCO panel nod To Manufacture, Market FDC of doxylamine and pyridoxine
AstraZeneca-Oxford COVID vaccine faces legal challenge in UK, says ReportAstraZeneca-Oxford COVID vaccine faces legal challenge in UK, says Report
Bayer begins Phase I study with GIRK4 inhibitor for atrial fibrillationBayer withdraws follicular lymphoma drug Aliqopa after further trial fails
Merck gets USFDA Priority Review for application for Keytruda plus standard of care as Perioperative treatment for Resectable Locally Advanced Head, Neck Squamous Cell CarcinomaMerck gets positive EMA Committee opinion for Keytruda plus Gemcitabine, Cisplatin for Biliary Tract...
Jubilant Radiopharma business receives ANDA approval for Technetium Sulfur Colloid InjectionJubilant Radiopharma business receives ANDA approval for Technetium Sulfur Colloid Injection
Biocon unveils Liraglutide for diabetes, obesity in NetherlandsBiocon arm gets UK MHRA marketing authorisation for ophthalmic drug Yesafili
Daiichi Sankyo Vanflyta approved in EU as First FLT3 Inhibitor specifically for newly Diagnosed FLT3-ITD Positive AMLDaiichi Sankyo Vanflyta approved in EU as First FLT3 Inhibitor specifically for newly Diagnosed...
Generate safety and efficacy data: CDSCO Tells Glenmark Over Glimipride, Lobeglitazone FDCGenerate safety and efficacy data: CDSCO Tells Glenmark Over Glimipride, Lobeglitazone FDC
X